 | | Vol. 13.24 – 8 July, 2021 |
| |
|
|
| Researchers showed that c-Myc greatly improved the trans-differentiation efficiency for hepatoblast-like cells (HLCs) from human umbilical cord MSCs, which remained highly efficient in reprogramming fibroblasts into HLCs.
[Stem Cell Research & Therapy] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Both placental-derived allogeneic preparations, cord blood platelet lysate and amniotic membrane extract eye drops, displayed regenerative and immunomodulatory capabilities.
[Scientific Reports] |
|
|
|
| The mechanism of human umbilical cord MSC-derived exosomal miR-181a was explored in nasopharyngeal carcinoma cell progression.
[Journal of Cancer Research and Clinical Oncology] |
|
|
|
| Scientists used the commercial Chromium platform to perform sc-ATAC-seq to measure chromatin accessibility in 11,611 single umbilical cord blood cells derived from one trisomy 18 syndrome patient and one healthy donor.
[Human Genomics] |
|
|
|
| Comprehensive analysis showed that expression of GAPDH and TATA box-binding protein was the most stable, whereas ZNF425 and OR8B8 were the least suitable candidate genes.
[DNA and Cell Biology] |
|
|
|
| Human umbilical cord MSCs-derived exosomal miR-100-5p inhibited cyclic strain-induced reactive oxygen species production and apoptosis in primary articular chondrocytes.
[Cell Biology International] |
|
|
|
| Researchers performed a cord blood hematopoietic cell transplantation with a reduced intensity conditioning on a nine-year-boy with adrenoleukodystrophy.
[Molecular Genetics and Metabolism Reports] |
|
|
|
|
| Over the past two decades, substantial advances have been made in the identification of Leydig cell sources for use in transplantation surgery, including the artificial induction of Leydig-like cells from different types of stem cells, for example, stem Leydig cells, MSCs, and pluripotent stem cells.
[Nature Reviews Urology] |
|
|
|
|
| Direct Biologics LLC announced that the FDA has approved the application for a Phase I/II trial under an Investigational New Drug (IND) protocol for the use of ExoFlo™ in the treatment of mild-to-moderate COVID-19. ExoFlo™ is an extracellular vesicle product isolated from human bone marrow MSCs.
[Direct Biologics LLC] |
|
|
|
|
| August 25 – 28, 2021
Virtual |
|
|
|
|
|
| | Stanford University – Palo Alto, California, United States |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | FibroBiologics – Houston, Texas, United States |
|
|
|
| | University of Southern California – Los Angeles, California, United States |
|
|
|
| | UT Southwestern Medical Center – Dallas, Texas, United Statess |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
